Prevalence of prostate cancer in placebo arm and GTC arm at the 6-month biopsy checkpoint and at the end of the 1-year study (12 months biopsy checkpoint)
| Study arm . | 6-months biopsy check . | 12-months biopsy check . | Total no. of CaPs diagnosed/total no. of recruited subjects . | Prevalence of prostate cancer . |
|---|---|---|---|---|
| Placebo | 6 of 30 | 3 of 24* | 9 of 30 | 30.0% |
| GTCs | 0 of 30 | 1 of 30 | 1 of 30 | 3.3% |
| P value (95% confidence, placebo vs. GTC) | <0.01 |
| Study arm . | 6-months biopsy check . | 12-months biopsy check . | Total no. of CaPs diagnosed/total no. of recruited subjects . | Prevalence of prostate cancer . |
|---|---|---|---|---|
| Placebo | 6 of 30 | 3 of 24* | 9 of 30 | 30.0% |
| GTCs | 0 of 30 | 1 of 30 | 1 of 30 | 3.3% |
| P value (95% confidence, placebo vs. GTC) | <0.01 |
Six patients, diagnosed with prostate cancer at the 6 months biopsy check, left the study and were not subjected to the subsequent 12 months biopsy check. Statistical analysis (t test analysis) shows that the difference in prostate cancer prevalence between the two arms was highly significant (P < 0.01).